Why CareDx Stock Jumped Today
Key Points
CareDx is helping to improve outcomes for transplant patients.
The health monitor's non-invasive tests are in high demand.
- 10 stocks we like better than CareDx ›
Shares of CareDx (NASDAQ: CDNA) climbed on Friday after the precision medicine diagnostics specialist lifted its full-year sales and earnings forecast.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Healthy growth
CareDx's revenue surged 52% year over year to $132 million in the second quarter.
The healthcare company's non-invasive tests help doctors monitor the health of transplant patients. The Centers for Medicare & Medicaid Services (CMS) affirmed coverage for CareDx's surveillance testing for kidney, heart, and lung transplants earlier this month.
"Revenue growth reflected continued demand across transplant programs, favorable reimbursement dynamics, and increases in testing activity across both surveillance and for-cause settings," the company said in its earnings release.
All told, CareDx's adjusted net income more than tripled to $20 million, or $0.37 per share. That was well above Wall Street's estimates, which had called for per-share profits of $0.23.
Raised guidance
These robust results prompted CareDx to increase its full-year revenue outlook to $490 million to $500 million, up from a prior forecast of $447 million to $465 million.
Management also now projects adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $66 million to $78 million, up from $43 million to $57 million.
CareDx's recently completed acquisition of oncology diagnostics provider Naveris should help accelerate its expansion.
"We have transformed CareDx into a differentiated precision molecular diagnostics company with a unique set of core competencies that position us for continued profitable growth," CEO John Hanna said.
Should you buy stock in CareDx right now?
Before you buy stock in CareDx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CareDx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $394,601!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,197,093!*
Now, it’s worth noting Stock Advisor’s total average return is 895% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of July 31, 2026.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
